[go: up one dir, main page]

ES2164704T3 - Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos. - Google Patents

Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.

Info

Publication number
ES2164704T3
ES2164704T3 ES94916937T ES94916937T ES2164704T3 ES 2164704 T3 ES2164704 T3 ES 2164704T3 ES 94916937 T ES94916937 T ES 94916937T ES 94916937 T ES94916937 T ES 94916937T ES 2164704 T3 ES2164704 T3 ES 2164704T3
Authority
ES
Spain
Prior art keywords
pct
image
alkylamino
sec
antimicrobial agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916937T
Other languages
English (en)
Inventor
Emilio Occelli
Sergio Lociuro
Romeo Ciabatti
Maurizio Denaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Bulk SpA
Original Assignee
Aventis Bulk SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Bulk SpA filed Critical Aventis Bulk SpA
Application granted granted Critical
Publication of ES2164704T3 publication Critical patent/ES2164704T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS ANTIBIOTICOS DE RIFAMICINAS DE LAS FORMULAS (I) Y (IA) QUE TIENEN EN LA POSICION 36 UN SUSTITUYENTE SELECCIONADO DEL ALQUILO (C{SUB,1}-C{SUB,8}), HALO, HIDROXI, ACILOXI (C{SUB,1}-C{SUB,4}), ALCOXI (C{SUB,1}-C{SUB,4}), ALQUILAMINO (C{SUB,1}-C{SUB,4}), DIALQUILAMINO (C{SUB,1}-C{SUB,4}) Y CARBONILOXI DE 4-OXO-3-PIRIDINILO SUSTITUIDO DE LA FORMULA (1) SE OBTIENEN HACIENDO REACCIONAR RIFAMICINA CON UN ACIDO MALONICO SUSTITUIDO DE FORMA ADECUADA. LOS COMPUESTOS DE LA INVENCION SON AGENTES ANTIMICROBIANOS PRINCIPALMENTE ACTIVOS CONTRA LAS BACTERIAS GRAM POSITIVAS Y BACTERIAS GRAM NEGATIVAS MALIGNAS Y PRESENTAN TAMBIEN UNA ACTIVIDAD ANTIMICROBIANA CONSIDERABLE CONTRA LAS ESPECIES MICROBIANAS RESISTENTES A LA RIFAMPICINA.
ES94916937T 1993-05-24 1994-05-05 Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos. Expired - Lifetime ES2164704T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93108337 1993-05-24
EP93110315 1993-06-29

Publications (1)

Publication Number Publication Date
ES2164704T3 true ES2164704T3 (es) 2002-03-01

Family

ID=26133222

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916937T Expired - Lifetime ES2164704T3 (es) 1993-05-24 1994-05-05 Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.

Country Status (12)

Country Link
US (1) US5786350A (es)
JP (1) JP3566962B2 (es)
KR (1) KR100325562B1 (es)
AT (1) ATE206427T1 (es)
AU (1) AU687817B2 (es)
CA (1) CA2160243C (es)
DE (1) DE69428535T2 (es)
DK (1) DK0700399T3 (es)
ES (1) ES2164704T3 (es)
IL (1) IL109691A (es)
PT (1) PT700399E (es)
WO (1) WO1994028002A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2185168C1 (ru) * 2001-01-26 2002-07-20 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Композиция для лечения туберкулеза
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US7238694B2 (en) * 2004-01-13 2007-07-03 Cumbre Pharmaceuticals, Inc. Rifamycin imino derivatives effective against drug-resistant microbes
WO2005070940A2 (en) * 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7256187B2 (en) 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7250413B2 (en) * 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
JP5236944B2 (ja) * 2004-07-22 2013-07-17 カムブァ、アイピー、ヴェンチュァズ、エル、ピー 微生物感染を治療するためのリファマイシン誘導体
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2895169A4 (en) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc METHODS OF ADMINISTERING RIFAXIMINE WITHOUT PRODUCING ANTIBIOTIC RESISTANCE
US11325920B2 (en) 2018-01-24 2022-05-10 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
EP4003200A4 (en) 2019-07-23 2023-08-02 The Rockefeller University ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF
CN119998299A (zh) 2022-09-30 2025-05-13 生物验证系统股份公司 用于治疗疾病的利福布汀类似物

Also Published As

Publication number Publication date
KR960702466A (ko) 1996-04-27
CA2160243C (en) 2007-08-28
JP3566962B2 (ja) 2004-09-15
PT700399E (pt) 2002-02-28
IL109691A (en) 1998-10-30
KR100325562B1 (ko) 2002-07-22
DK0700399T3 (da) 2001-11-26
AU687817B2 (en) 1998-03-05
JPH08511249A (ja) 1996-11-26
AU6843094A (en) 1994-12-20
WO1994028002A1 (en) 1994-12-08
US5786350A (en) 1998-07-28
ATE206427T1 (de) 2001-10-15
IL109691A0 (en) 1994-08-26
DE69428535D1 (de) 2001-11-08
DE69428535T2 (de) 2002-08-01
CA2160243A1 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
ES2164704T3 (es) Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.
WO2005014585A8 (en) Halogenated quinazolinyl nitrofurans as antibacterial agents
AU686222B2 (en) Cyclodepsipeptide compound
SI0868424T1 (en) 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinone derivatives, their preparation and their use as anti-bacterial agents
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
GB0007405D0 (en) Compounds
AU5115193A (en) Method of preparing taxane derivatives
PL344049A1 (en) Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
BR0016605A (pt) Oxazolidinonas possuindo uma funcionalidade sulfoximina e seus usos como agente antimicrobiano
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
TR200001330T2 (tr) Oksazolidinon türevleri ve farmasötik terkipler
NZ503897A (en) 3,6-hemiketals from the class of 9a-azalides
EP1262477A4 (en) ANTIBACTERIAL AGENTS EFFECTING ACID-RESISTANT BACTERIES CONTAIN PYRIDINE CARBONIC ACIDS AS AN ACTIVE ACTIVE SUBSTANCE
CO5190676A1 (es) Combinaion antibacterial sinergistica hideogenada y metodo
AU2001278428A1 (en) Macrolides
WO2004043928A3 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
SI0808326T1 (en) Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics
CA2380455A1 (en) 9a-azalides with antibacterial activity
AU6076500A (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents
GB9115272D0 (en) Benzimidazole anthelmintics
NO20065889L (no) 3-`4-{6-substituert alkanoyl)pyridin-3-yf}-3-fenyl!-5-(1 H-1,2,3-triazol-1-ylmetyl)-1,3-oksazolidin-2-oner som antibakterielle midler.
EP0601197A4 (en) DERIVATIVES OF 5-AMINOCHINOLONE CARBOXYLIC ACID AND ANTIBACTERIAL AGENTS CONTAINING IT AS AN ACTIVE INGREDIENT.
DE602006001731D1 (de) Verwendung von pyrimidinetrion-derivaten als acetylcholinesterase-hemmer, diese enthaltende zusammensetzungen und deren verwendungen
WO2002050081A3 (en) Antimicrobial agents
AU6742694A (en) Amidothiophosphate derivative and insecticide, nematocide and acaricide containing the same as active ingredient

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 700399

Country of ref document: ES